Tvardi Therapeutics Selects Ulcerative Colitis As Initial Indication For TTI-109, Says Phase 1 Showed Up To 76% Reduction In Th17 Subsets; Trial Planned For 2027

뉴스 본문을 불러오고 있어요.

Tvardi Therapeutics Selects Ulcerative Colitis As Initial Indication For TTI-109, Says Phase 1 Showed Up To 76% Reduction In Th17 Subsets; Trial Planned For 2027 | 웨이프 WAPE

Tvardi Therapeutics Selects Ulcerative Colitis As Initial Indication For TTI-109, Says Phase 1 Showed Up To 76% Reduction In Th17 Subsets; Trial Planned For 2027

기사 요약

관련 종목

댓글 —